Voriconazole Therapeutic Drug Monitoring-Reference-Cited by-同舟云学术

Voriconazole Therapeutic Drug Monitoring

Published:2006-04 Issue:4 Volume:50 Page:1570-1572
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Smith J.¹,Safdar N.¹,Knasinski V.¹,Simmons W.²,Bhavnani S. M.³,Ambrose P. G.³,Andes D.¹⁴

Affiliation:

1. University of Wisconsin, Department of Medicine, Section of Infectious Diseases, Madison, Wisconsin

2. University of Wisconsin, Department of Pharmacy, Madison, Wisconsin

3. Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York

4. University of Wisconsin, Department of Medical Microbiology and Immunology, Madison, Wisconsin

Abstract

ABSTRACT We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship ( P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 μg/ml, while disease progressed in 44% ( n = 18) of patients with concentrations below 2.05 μg/ml.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.50.4.1570-1572.2006

Reference29 articles.

1. Alexander, B., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation27:868-871.

2. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

3. Begg, E. J., B. L. Murray, and C. J. Kirkpatrick. 1999. The therapeutic monitoring of antimicrobial agents. Br. J. Clin. Pharmacol.47:23-30.

4. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J.15:255-259.

5. Desta, Z., X. Zaho, J. G. Shin, and D. A. Flockhart. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet.41:913-958.

Cited by 352 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing;The Pharmacogenomics Journal;2023-11

2. Chemistry and Therapeutic Aspect of Triazole: Insight into the Structure-activity Relationship;Current Pharmaceutical Design;2023-09

3. Assessing the safety profile of voriconazole use in suspected COVID-19-associated pulmonary aspergillosis–a two-centre observational study;Medical Mycology;2023-06

4. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing;2023-05-24

5. Higher Weight-Based Doses Are Required to Achieve and Maintain Therapeutic Voriconazole Serum Trough Concentrations in Children;The Journal of Pediatric Pharmacology and Therapeutics;2023-05-01